{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023047","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.599617+00:00","generated_at":"2026-06-11T17:45:51.542858+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulse Biosciences Q2 net loss narrows to $9.9M; cash $58.7M after $65M private placement","bullets":["GAAP net loss ($9.9M) vs ($14.0M) YoY; Non-GAAP net loss ($8.5M) vs ($11.9M).","Cash totaled $58.7M at June 30, 2023, up from $14.8M a year ago; Q2 warrant exercises added $14.6M gross.","Closed $65M private placement with Executive Chairman Robert Duggan, cancelling all debt owed to him.","Preclinical: nsPFA cardiac clamp ablates 25mm tissue in 1.25 sec; catheter isolates pulmonary veins in ~5 sec.","First-in-human study of nsPFA for benign thyroid nodules showed positive safety and tissue response."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023047","json":"https://secwatch.observer/filing/0001437749-23-023047.json","markdown":"https://secwatch.observer/filing/0001437749-23-023047.md","text":"https://secwatch.observer/filing/0001437749-23-023047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923023047/0001437749-23-023047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923023047/plse20230809_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:45:51.542858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ade852c3f669ee56138ddcfd39d13a1ca4bc9129","claim":"PULSE BIOSCIENCES, INC. reported the fiscal quarter ended June 30, 2023 results: net income ($9.9) million.","evidence_excerpt":"GAAP net loss for the three months ended June 30, 2023 was ($9.9) million compared to ($14.0) million for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923023047/0001437749-23-023047-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended June 30, 2023"},{"label":"Net income","value":"($9.9) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}